Hospital Universitario Central de Asturias -ko ikertzaileekin lankidetzan egindako argitalpenak (28)

2021

  1. Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group

    Transplant Infectious Disease, Vol. 23, Núm. 4

  2. Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment

    Bone Marrow Transplantation, Vol. 56, Núm. 6, pp. 1281-1290

  3. Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group

    American Journal of Transplantation, Vol. 21, Núm. 1, pp. 258-271

  4. Defibrotide in hematopoietic stem cell transplantation: A multicenter survey study of the Spanish Hematopoietic Stem Cell Transplantation Group (GETH)

    European Journal of Haematology, Vol. 106, Núm. 6, pp. 842-850

2020

  1. Agreements and uncertainties in autologous haematopoietic stem cell mobilization and collection. A Spanish consensus document

    Bone Marrow Transplantation, Vol. 55, Núm. 4, pp. 811-817

2019

  1. Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy

    Hematology/ Oncology and Stem Cell Therapy, Vol. 12, Núm. 4, pp. 194-203

2018

  1. A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms

    Blood Advances, Vol. 2, Núm. 14, pp. 1719-1737

  2. Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment

    Hematological Oncology, Vol. 36, Núm. 5, pp. 765-772

  3. Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: A long-term follow-up analysis from the Spanish GELTAMO registry

    Bone Marrow Transplantation

2017

  1. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure

    Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 10, pp. 1631-1640

  2. Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma

    Cancer Medicine, Vol. 6, Núm. 12, pp. 2766-2774

  3. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 8, pp. 2359-2367

2016

  1. Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS

    Bone Marrow Transplantation, Vol. 51, Núm. 7, pp. 961-966

  2. UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation

    Bone Marrow Transplantation, Vol. 51, Núm. 1, pp. 79-82

2015

  1. A registry-based study of non-Aspergillus mould infections in recipients of allogeneic haematopoietic cell transplantation

    Clinical Microbiology and Infection

  2. Effect of mismatching for mHA UTA2-1 on clinical outcome after HLA-identical sibling donor allo-SCT

    Bone Marrow Transplantation

  3. Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: A randomized controlled trial

    Clinical Infectious Diseases, Vol. 60, Núm. 3, pp. 405-414

2014

  1. Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation

    Haematologica, Vol. 99, Núm. 10, pp. 1632-1637

2013

  1. Tratamiento de infecciones fúngicas en pacientes hematológicos de alto riesgo. La respuesta de AmBisome no se modifica con el uso previo de azoles de amplio espectro

    Revista Espanola de Quimioterapia, Vol. 26, Núm. 1, pp. 64-69

  2. Tratamiento de las infecciones fúngicas invasoras en pacientes hematológicos de alto riesgo: ¿Qué hemos aprendido en los pasados 10 años?

    Revista Espanola de Quimioterapia, Vol. 26, Núm. 4, pp. 378-386